{
    "clinical_study": {
        "@rank": "139736", 
        "arm_group": [
            {
                "arm_group_label": "Completion axillary treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Completion axillary treatment according to the Dutch breast cancer guideline"
            }, 
            {
                "arm_group_label": "No completion axillary treatment", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "STUDY AIM To decrease the number of breast cancer patients receiving overtreatment of the\n      axilla, in order to positively influence the axillary morbidity rate and quality of life.\n\n      PRIMARY OBJECTIVE To determine whether omitting completion axillary treatment is not\n      inferior to the current axillary treatment regimen in sentinel node positive breast cancer\n      patients undergoing a mastectomy, in terms of regional recurrence rate.\n\n      HYPOTHESIS Completion axillary treatment can be safely omitted in sentinel node positive\n      breast cancer patients undergoing a mastectomy. This will lead to a decreased axillary\n      morbidity rate and to an increased quality of life, with non-inferior regional control,\n      distant-disease free- and overall survival rates."
        }, 
        "brief_title": "Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy", 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  Aged 18 years or older\n\n          -  Pathologically confirmed invasive unilateral breast carcinoma\n\n          -  A clinical T1-2 tumour (including multifocal or multicentric breast cancer)\n\n          -  Will be or is treated with mastectomy\n\n          -  Clinically node negative: no signs of axillary lymph node metastases at physical\n             examination and preoperative axillary ultrasound (or negative cyto-/histopathology)\n\n          -  Sentinel lymph node procedure and its pathologic evaluation should be performed\n             according to the Dutch breast cancer guideline\n\n          -  pN1mi(sn) or pN1(sn): at least one and a maximum of three axillary sentinel lymph\n             nodes containing micro- and/or macrometastases\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Clinically node positive pre-operative\n\n          -  Sentinel lymph nodes only containing isolated tumour cells (<0.2 mm)\n\n          -  Solitary parasternal sentinel lymph node metastasis (pN1b)\n\n          -  Bilateral breast cancer\n\n          -  Irradical resection of primary tumour at time of randomization (applicable in case\n             the mastectomy is performed before randomization)\n\n          -  Evidence of metastatic disease\n\n          -  History of invasive breast cancer\n\n          -  Previous treatment of the axilla with surgery or radiotherapy (except surgery for\n             hidradenitis suppurativa or for other superficially located skin lesions, such as\n             naevi)\n\n          -  Pregnant or nursing\n\n          -  Other prior malignancies within the past 5 years (except successfully treated basal\n             cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in\n             situ of the ipsilateral or contralateral breast) or unsuccessfully treated\n             malignancies > 5 years before randomization\n\n          -  Unable or unwilling to give informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "878", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112682", 
            "org_study_id": "BOOG 2013-07", 
            "secondary_id": "KWF UM 2013-5920"
        }, 
        "intervention": {
            "arm_group_label": "Completion axillary treatment", 
            "description": "Completion axillary treatment according to the Dutch breast cancer guideline", 
            "intervention_name": "Completion axillary treatment", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sentinel lymph node metastasis", 
            "Completion axillary lymph node dissection", 
            "Axillary radiotherapy"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Marjolein L Smidt, MD, PhD", 
                "phone": "+31433877477"
            }, 
            "facility": {
                "address": {
                    "city": "Maastricht", 
                    "country": "Netherlands", 
                    "state": "Limburg", 
                    "zip": "6202 AZ"
                }, 
                "name": "Maastricht University Medical Centre+"
            }, 
            "investigator": {
                "last_name": "Marjolein L Smidt, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Value of Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy. A Dutch Randomized Controlled Multicentre Trial.", 
        "overall_contact": {
            "last_name": "Marjolein L Smidt, MD, PhD", 
            "phone": "+31433877477"
        }, 
        "overall_official": [
            {
                "affiliation": "Maastricht University Medical Centre+, Maastricht, the Netherlands", 
                "last_name": "Marjolein L Smidt, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud University Medical Centre, Nijmegen, the Netherlands", 
                "last_name": "Hans JW de Wilt, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2027", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Regional recurrence is defined as tumour recurrence and as residual tumour that became clinically apparent in ipsilateral axillary, infraclavicular and supraclavicular lymph nodes (pathologically proven).", 
            "measure": "Regional recurrence rate", 
            "safety_issue": "No", 
            "time_frame": "up to ten years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Maastricht University Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Borstkanker Onderzoek Groep", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dutch Cancer Society", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Maastricht University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Maastricht University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}